International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Commentary: Cytokine inhibitors have a low prevalence of SARS-CoV-2 seroconversion

computer with words expert commentary

Johann Gudjonsson, MD, PhD
University of Michigan
Ann Arbor, Michigan, United States
IPC Board Member

PUBLICATIONS

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have a low prevalence of SARS-CoV-2 seroconversion. Simon D, Tascilar K, Krönke G, Kleyer A, Zaiss MM, Heppt F, Meder C, Atreya R, Klenske E, Dietrich P, Abdullah A, Kliem T, Corte G, Morf H, Leppkes M, Kremer AE, Ramming A, Pachowsky M, Schuch F, Ronneberger M, Kleinert S, Maier C, Hueber AJ, Manger K, Manger B, Berking C, Tenbusch M, Überla K, Sticherling M, Neurath MF, Schett G. Nat Commun. 2020 Jul 24;11(1):3774. doi: 10.1038/s41467-020-17703-6. PMID: 32709909; PMCID: PMC7382482.

COMMENTARY

Do Biologics Protect Against COVID-19 Infection?

In a recent publication in Nature Communications1 a team from Friedrich-Alexander University in Germany described their findings from a cross-sectional population cohort study on the prevalence of anti-SARS-CoV-2 immunoglobulin G (IgG) in patients with chronic immune-mediated inflammatory diseases (IMIDs) on cytokine-blocking treatments.  This patient cohort was compared against subjects with IMIDs, not on cytokine inhibitors, health care workers, and healthy controls.   The findings from this study showed that patients with IMID on cytokine inhibitors had a lower prevalence of anti-SARS-CoV-2 IgG response compared to the other three cohorts.  To assess whether this could be accounted for by differences in social exposure between the groups, the investigators assessed exposure risk variables in the four groups and found those to be similar between the two IMID groups and less than that of health care workers.  These findings led the authors to conclude that patients with IMIDs on cytokine inhibitor therapies have reduced susceptibility to SARS-CoV2 infection compared with patients not receiving cytokine-inhibitors, as well as the general population.

While these findings are highly intriguing, they have to be taken with caution.  Thus, while the findings described here are significant, they are based on very small sample sizes and lack validation from an independent cohort.  Furthermore, using a survey to control for exposure is likely inadequate as it may not capture subtle changes in behavior that are not easily caught on survey questionnaires.  In addition, while these treatments inhibit specific inflammatory pathways and may be protective against more severe COVID-192, it is hard to envision how they’d prevent seroconversion of exposed patients.  This is supported by studies showing blunted, but not absent, vaccination responses to influenza vaccine3.  Lastly, if the implications of this study hold true, it would also have potential implications regarding the utility of vaccinating patients for COVID while on biologics.

In summary, while these findings are intriguing, the message from this paper that patients with IMIDs on biologics are protected against COVID-19 infection has to be taken with great caution. More extensive and robust studies are required before we can confidently determine that biologics protect against SARS-CoV-2 infection.

Reference:

  1. Simon D, et al.  Nat Communications 2020, 3774
  2. Winthrop KL, et al.  Ann Rheum Disease, 2021 80(2):269-271
  3. Gelinck LBS, et al.  Ann Rheum Dis 2008, 67(5):713-6.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Categories

Tags

Recent Posts

PASI 90 blog post with Dr. Maskin

Access to Biologics in Argentina: Rethinking Time to PASI 90

Blog Post - Psoriasis Hub

IPC Partners with Scientific Education Support to Create New Psoriasis and Psoriatic Arthritis Hub

Blog -Expert Insights-Erica-Alba (1)

Monkeypox Symptoms, Treatment, Prevention, and Impact on Psoriasis Patients

Also Read

Enikö Sonkoly

Focus on Psoriasis: A Report from the European Academy of Dermatology and Venereology 31st Annual Congress (EADV)

The European Academy of Dermatology and Venereology (EADV) organized its 31st congress in Milano, Italy, under the parole “Designing the Future of Dermatology and Venereology.” The event took place from September 7 – 10, 2022, as a hybrid meeting with the option of attending virtually or in person. The following congress report includes fifteen summaries of presentations focusing on psoriasis. You can download the full report or read the summary.

Read More
Filip Rob Commentary graphic
deucravacitinib

Commentary: Deucravacitinib Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy and Safety Results from the 52-week, Randomized, Double-blinded, Placebo-controlled Phase 3 POETYK PSO-1 Trial

The United States Food and Drug Administration (FDA) has approved deucravacitinib to treat psoriasis. Recently, 52-week efficacy and safety data of deucravacitinib were compared and contrasted with placebo and apremilast. The outcome of this comparative study lends support for the position of deucravacitinib in the spectrum of treatments for psoriasis.

Read More
Blog - Commentary - Alexander Egeberg - graphic
Adalimumab

Commentary: Drug Survival Associated with Effectiveness and Safety of Treatment with Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients with Psoriasis

Real-world evidence studies become crucial to achieving the evidence needed in clinical practice. But how are data evaluated in the complexity of the real world? Alexander Egeberg, MD, PhD, DMSc, discusses a present study that examined drug survival among 16,122 treatment courses of biologic therapy with either guselkumab, ixekizumab, secukinumab, ustekinumab, or adalimumab, using United Kingdom registry data.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.